Molecular Formula | C19H20FN5O |
Molar Mass | 353.39 |
Density | 1.34 |
Boling Point | 568.4±60.0 °C(Predicted) |
Solubility | DMSO: ≥ 48 mg/mL |
pKa | 9.91±0.10(Predicted) |
Storage Condition | 2-8°C(protect from light) |
In vitro study | SB 242235 (0-10 μM) dose-dependently inhibits the activation of MAPKAP K2 with an IC 50 of 1.0 μM in human chondrocytes stimulated with IL-1β. SB 242235 inhibits intracellular p38 activity, MAPKAP K2 was then isolated from these cells and assayed using HSP27 as a substrate. Western Blot Analysis Cell Line: Human chondrocytes Concentration: 0 μM,0.01 μM,0.1 μM,1 μM,10 μM Incubation Time: 15 minutes Result: Dose-dependently inhibited the activation of MAPKAP K2 with an IC 50 of 1.0 μM. |
In vivo study | SB242235 (100 mg/kg; p.o.) abolishes MAP-KAPK-2 activity and HSP27 phosphorylation. SB242235 inhibits expression of the pro-inflammatory cytokines interleukin (IL)-6 and KC (murine IL-8) and COX-2. SB-242235 is demonstrated non-linear elimination kinetics that manifested as a decrease in clearance with increasing dose and apparent oral bioavailability > 100% at high oral doses in rat and monkey. Animal Model: Female SKH-1 hairless mice (4–6 weeks) Dosage: 100 mg/kg Administration: Oral administered, 30 minutes prior to ultraviolet B (UVB) irradiation Result: Abolished MAP-KAPK-2 activity and heat shock protein 27 (HSP27) phosphorylation. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.83 ml | 14.149 ml | 28.297 ml |
5 mM | 0.566 ml | 2.83 ml | 5.659 ml |
10 mM | 0.283 ml | 1.415 ml | 2.83 ml |
5 mM | 0.057 ml | 0.283 ml | 0.566 ml |